Noom Health partners with top health plans and employers to offer millions of Americans a suite of metabolic health solutions including Noom Clinical (Noom Med, Noom SmartRx, and NoomRx programs), Noom Weight, Noom Diabetes, and Noom Diabetes Prevention Program
Piotrowski K, Becker M, Zugwurst J, Biller-Friedmann I, Spoettl G, Greif M, Leber AW, Becker A, Laubender RP, Lebherz C, Goeke B, Marx N, Parhofer KG, Lehrke M: Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans
And in 2021, the results from a series of five STEP trials (Semaglutide Treatment Effect in People with obesity) demonstrated marked weight loss even in individuals without type 2 diabetes (T2DM): Phase 3, for example, showed an average loss of about 15 percent over 68 weeks, more than double achieved by any prior obesity drug
Running viability, cytotoxicity, and apoptosis as separate assays on separate plates means more sample, more time and more variability between measurements